Sign in to view content

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2024

Related

Phase 3 GUARD Trial of ADX-2191 (Methotrexate for Intravitreal Administration) to Prevent Proliferative Vitreoretinopathy and Other Postoperative Complications
Christina Joy Flaxel, MD
Annual Meeting Talks
2023
Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019
Future Direction of the DRCR Retina Network
Daniel F. Martin, MD
Updates from the Field
2019

Category: Hereditary Retinal Disease & Genetics

See more